John F. Seymour, MBBS, PhD
The regimen of venetoclax (Venclexta) plus rituximab (Rituxan) lowered the risk of disease progression or death by 83% versus bendamustine (Treanda) plus rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to findings from the phase III MURANO trial now published in the New England Journal of Medicine.
After a median follow-up period of 23.8 months, the progression-free survival (PFS) rate per investigator assessment was 84.9% for venetoclax/rituximab and 36.3% for BR (HR, 0.17; 95% CI, 0.11-0.25; P
<.001). An independent review committee found a PFS benefit for the venetoclax regimen that was consistent with the investigator findings (HR, 0.19; 95% CI, 0.13-0.28; P
... to read the full story